PIK-108 is a small molecule allosteric inhibitor selectively targeting the PI3Kbeta and PI3Kdelta catalytic isoforms. This compound is a valuable research tool for investigating PI3K signaling in oncology and immunology, supporting both in vitro biochemical assays and in vivo disease model studies.